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Abstract
We would like to present a patient with a classical phenotype of a rare disorder - Cowden syndrome, its
diagnostics and management challenges. A breast surgeon has to be aware of this rare condition when treating a
patient with breast manifestations of Cowden syndrome and has to refer the patient to a clinical geneticist for
further evaluation. Sequencing of the PTEN gene showed the Asp24Gly mutation. According to the latest literature
data, the lifetime risk of breast cancer for Cowden syndrome patients is 81% and surgery is a justified option to
reduce the risk of breast cancer. Bilateral risk-reducing mastectomy with immediate reconstruction was performed
to eliminate further risk of breast cancer. 3 years after the risk-reducing breast surgery the patient is satisfied with
the outcome. This is to our best knowledge the first reported Cowden syndrome case with follow-up data after
risk-reducing measures have been taken.
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Background
Cowden syndrome (CS) is an uncommon disorder with
an estimated incidence of 1 per 200,000 of the popula-
tion, characterized by germline mutations in the tumor
suppressor gene PTEN [1,2]. CS is associated with highly
variable symptoms and signs, meaning that it might be
underdiagnosed; in addition, approximately 20% of CS
patients have no identified genetic explanation of their
phenotypic features [3].
CS is characterized by multiple hamartomas in a variety
of tissues and indicates an increased risk of developing
malignancies. In female patients the syndrome is asso-
ciated with up to 50% lifetime risk of developing breast
cancer, 5-10% risk of developing endometrial cancer, and
10% lifetime risk of developing follicular thyroid cancer
[4]. In recent reports the elevated lifetime cancer risk in
Cowden syndrome patients or in individuals with germ-
line PTEN mutations is up to 85% for breast cancer, up
to 35% for thyroid cancer, and up to 28% for endometrial
cancer [5,6]. Lifetime cancer risks are now extending to
kidney cancer and colorectal cancer (up to 33% and 16%,
respectively).
Other features of the disorder include macrocephaly,
gastrointestinal polyps, benign breast, thyroid and endo-
metrial manifestations, and characteristic mucocutaneous
lesions. The diagnosis of CS in most cases is primarily
based on the presence of mucocutaneous features, esti-
mated to have 99% penetrance before the age of 30 [7]. A
correlation between an identified PTEN mutation and
breast cancer diagnosis in CS has been reported [3].
Breast cancers are most often diagnosed in CS patients at
the age of 38-46 [8]. 34% of female CS patients diagnosed
with breast cancer had bilateral diseases [5].
Case presentation
The proband is a female born in Latvia in 1973. She has
a remarkable medical history from the age of 32 when
she underwent total thyroidectomy due to a benign nod-
ular goiter. Cavernous angioma of the right temporal
lobe (2.1 × 1.7 cm) was present on brain MRI with con-
trast and liver angioma was detected at a size of 0.8 cm
on abdominal ultrasound at the age of 33.
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ondary to metrorrhagia. Stage IA endometrial adenocarci-
nomawas detected at 34 and a following hysterectomy
with bilateral salpingo-oophorectomy was performed.
Gastroscopy at the age of 34 revealed numerous asymp-
tomatic polyps 6 cm below the cardia level (4-10 mm in
size). Biopsies from the polyps were taken, histology
showed hyperplastic polyps without malignancy.
At the age of 35 she visited a breast surgeon, complain-
ing of palpable breast lesions. She had already had several
bilateral breast fibroadenomas u r g e r i e si nt h ep a s t .T 1 -
w e i g h e db r e a s tM R I( F i g u r e1 )s h o w e dm u l t i p l e ,w e l l -
circumscribed, oval, bilateral high signal intensity lesions.
The clinical geneticist considered an initial diagnosis of
CS according to the diagnostic criteria updated by the US
NCCN 2008 [5]. The diagnosis was based on the presence
of two major and three minor criteria (Table 1). The major
criteria were endometrial carcinoma and macrocephaly.
The exhibited minor criteria were nodular goiter, lipomas,
and gastric polyps. Hamartomatous mucocutaneous
lesions in the Latvian proband were not confirmed patho-
logically. A similar case has been described where the typi-
cal skin features were not reported before 55 years of age,
whereas abnormal findings in several organs at a relatively
young age were indicative [9]. Only focused examination
revealed subtle skin lesions that are also widely spread in
the general population. In our case, the presence of endo-
metrial malignancy at such an early age was striking, and it
was indicative of possible inheritance. Another significant
factor was bilateral exuberant breast lesions.
The diagnosis was further supported by the presence
of the missense mutation Asp24Gly in the PTEN gene.
DNA was isolated from blood using the FlexiGene (Qia-
gen) kit and the PTEN gene was sequenced as described
earlier [10]. No clinically suspected or genetically estab-
lished cases of CS among the 2,070,000 inhabitants of
Latvia have been reported so far.
The family history of the proband did not reveal any sig-
nificant pathology, a DNA sample was taken from the pro-
band’s parents and one of the two sibs who all appeared to
be non-carriers of the mutation. Consequently, we can
assume that the proband has received a de novo germline
mutation, but it is impossible to establish its either pater-
nal or maternal origin. The proband’s level of intelligence
is standard, she has socially active parents and two sisters.
Preoperative ultrasound-guided breast fine-needle
aspiration from several abnormal areas was obtained, but
no malignancy was detected.
Considering high future risk of breast cancer, prophylac-
tic bilateral mastectomy was recommended by the multi-
disciplinary team as the most effective available risk-
reducing measure for breast cancer. The indications of
risk-reducing mastectomy and alternative management
options were discussed with the patient. The patient chose
to undergo a risk-reducing surgery. Bilateral skin-sparing
mastectomy with immediate two stage expander/implant
reconstruction was successfully performed. At the first
stage, immediately after skin-sparing mastectomy, tissue
expanders (Eurosilicone Vertex tissue expander, 500 cc)
were placed in a complete submuscular position under the
pectoralis major muscle. Partially for coverage the serratus
anterior and pectoralis minor muscles were elevated.
Intraoperatively, each tissue expander was filled with
200 ml saline.
The surgical specimen revealed mastopathy areas with
features of fibroadenoma, areas of ductal hyperplasy,
fibrosing adenosis, apocrine metaplasia, microcalcinates,
and intracanalicular fibroadenoma.
During 6 weeks the expansion of tissue expanders was
started biweekly with 50 - 100 ml until 550 ml were
reached in each side.
Eight months later the expanders were replaced by per-
manent implants (Eurosilicone Cristalline Vertex Paragel,
102 N, high profile, 500 cc). Finally, nipple reconstruction
using C-V flap technique was performed seven months
after the placement of the implants. A three-year follow-up
shows good clinical results and the proband feels well.
Screening gastroscopy, colonoscopy, and abdominal CT
scan were performed. Polyps were found only in the sto-
mach and duodenum, histopathologic examination of biop-
sies showed hyperplastic polyps. Abdominal CT scan
revealed that liver hemangioma had increased in size up to
3.5 cm and a new hemangioma of 3.3 cm in size was
detected.
Discussion
Because of the rarity of Cowden syndrome the manage-
ment examples are insufficient in existing literature.
Figure 1 T1-weighted breast MRI. Representation of well-
circumscribed, oval, multifocal, bilateral high signal intensity lesions.
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in CS patients is the same as for the sporadic counter-
parts in the general population. The management of an
individual with a PTEN mutation relates to a significant
aspect - increased cancer surveillance, regarding the pre-
disposition to a variety of cancers. The National Cancer
Comprehensive Network (NCCN) issues are the most
widely approved guidelines for the management of can-
cer risk in individuals with CS.
Recent studies have reported gastrointestinal polyps in
93% of PTEN mutation carriers and an increased life-
time risk for colorectal cancer of up to 16% in patients
with CS [5,11]. Half of the CS patients have hyperplastic
polyps [12], as in this case, suggesting that routine colo-
noscopy should be considered.
Elevated lifetime risk (15% and 33.6%) for renal cancer
has also been found [5,6]. The authors recommended
annual abdominal ultrasound or CT scanning and
urinalysis.
Breast cancer is the most common component cancer
of CS. Pilarski et al., reporting on the largest single
cohort of PTEN-positive patients published to that date,
found breast cancer in 32% (28/90) of female patients,
with the mean age at molecular testing of 47.6 years
(range 33-64 years) [13]. Recently, Tan et al. reports esti-
mated the lifetime risk for breast cancer in patients with
a PTEN mutation at 85.2% [6]. Similarly, Riegert-Johnson
et al. ascertained breast cancer risk at 81% in patients
meeting accepted diagnostic criteria for CS [5]. These
two studies included a large cohort of patients (respec-
tively, 368 and 210) for the first time and reported signifi-
cantly higher cumulative lifetime risks than those
previously published. Risk of breast cancer up to 80% is
usually observed in BRCA1 and BRCA2 mutation carriers
[14,15].
The presented patient is the only carrier of the
Asp24Gly mutation in the PTEN gene among her tested
family members (father, mother and sister) and the only
one who is affected by CS. Obviously, this is not sufficient
to certainly identify this mutation as a cause of CS but it
should be noted that in tumors of various localizations
(central nervous system, endometrium, intestine, ovary
and urinary tract) somatic mutations in this position
(D24G, D24E, D24Y and D24N) have been found (COS-
MIC). This mutation was predicted to be possibly dama-
ging (score 0.539) by PolyPhen-2 analysis.
To control the possible development of breast cancer
for CS patients without a family history, the NCCN
recommends mammography and breast magnetic reso-
nance imaging to be commenced at the age of 30-35 (or
5-10 years before the earliest known breast cancer in the
family or whichever is earlier) [5]. The analysis of medical
publications shows that 7% of CS breast cancers occurred
prior to the recommended onset of radiographic screen-
ing by NCCN [5].
Breast cancer prevention also involves removal of the
breast prior to the development of malignancy. At pre-
sent, the most frequent indications for bilateral risk-redu-
cing mastectomy are high risk histology (such as a typical
ductal or lobular hyperplasia and lobular carcinoma in
situ), strong family history and positive mutation in the
BRCA1 or BRCA2 genes [16]. Although there are no data
regarding risk-reducing surgery in females with Cowden
syndrome, the option of risk-reducing mastectomy
should be discussed on a case-to-case basis. It has been
proven [17] that bilateral prophylactic mastectomy
reduces the risk of breast cancer by 90% in women with
intact ovaries and by 95% in women who have undergone
both prophylactic mastectomy and oophorectomy in the
case of BRCA1/2 gene mutation carriers. Only two cases
Table 1 Presence of the diagnostic criteria of Cowden syndrome in proband according to US National Comprehensive
Cancer Network (2008)
Pathognomonic criteria Lhermitte-Duclos disease (dysplastic cerebellar gangliocytoma) no
Mucocutaneous lesions (trichilemmomas, acral keratoses, papillomatous lesions, mucosal lesions) no
Major criteria Breast cancer no
Thyroid cancer (especially follicular) no
Endometrial cancer yes
Macrocephaly (≥ 97% percentile) yes
Minor criteria Other thyroid lesions (e.g., adenoma, multinodular goiter) yes
Mental retardation (IQ ≤ 75) no
Gastrointestinal hamartomas yes
Fibrocystic breast disease no
Lipomas yes
Fibromas no
Genitourinary tumors (especially renal cell carcinoma) no
Genitourinary structural malformations no
Uterine fibroids no
Melbārde-Gorkuša et al. Hereditary Cancer in Clinical Practice 2012, 10:5
http://www.hccpjournal.com/content/10/1/5
Page 3 of 5of bilateral risk-reducing mastectomy for CS patients
with no breast lesions where PTEN mutation is geneti-
cally confirmed have been described thus far [18].
The hamartomatous lesions of the breasts for CS
patients are frequently diffuse, multifocal, bilateral and
feature various complex histopathologic abnormalities
[4]. The lesions of the breasts detected by MRI in our
proband were so extensive that obtaining histological
samples from all the suspicious sites was impossible. An
individual breast cancer risk assessment for a CS patient
is complicated because of the rarity of the syndrome.
In some CS cases diagnostic difficulty is associated with
dense breast tissue. This may lead to multiple biopsies
with increased scarring during healing and further com-
plicated physical examination and radiological evaluation.
Moreover, the benign findings at core biopsies do not
exclude that invasive carcinoma might arise within den-
sely fibrotic, hamartomatous areas of the breast [12]. Psy-
chological factors should be considered as well. The
stress of constant surveillance and the threat of multiple
biopsies may lead CS patients to choose bilateral risk-
reducing mastectomy even if indications do not corre-
spond to consensus guidelines.
In conclusion, as risk-reducing surgery is becoming a
more acceptable option for high risk individuals, sur-
geons need to balance their decisions between individual
risk assessment, potential psychological benefits and
accepted guidelines [17].
If Cowden syndrome is confirmed by molecular exami-
nations, risk-reducing bilateral mastectomy may be an
effective preventive measure of breast cancer. This is to
our best knowledge the first reported CS case with follow-
up data after risk-reducing measures have been taken..
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